Publications:  Mr Aaron Prendergast

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al.(2020). Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). Nature Medicine vol. 26, (6)

Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. (2020). MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue. JOURNAL OF CLINICAL ONCOLOGY. vol. 38,

Suarez Rodriguez C, Larkin JMG, Patel P, Perez Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. (2020). Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 38,

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al.(2020). Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. Journal of Clinical Oncology vol. 38, (5) 423-433.

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al.(2019). Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine vol. 25, (11) 1706-1714.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al.(2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncology vol. 5, (11) 1556-1563.

Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. (2019). STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. ANNALS OF ONCOLOGY. vol. 30,

Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, Stenson I, Prendergast A et al.(2019). Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: A diagnostic accuracy and cost-effectiveness study. Gut vol. 68, (9) 1642-1652.

Powles T, Larkin JMG, Patel P, Perez-Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. (2019). A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). JOURNAL OF CLINICAL ONCOLOGY. vol. 37,

Atkin W, Cross AJ, Kralj-Hans I, Macrae E, Piggott C, Pearson S, Wooldrage K, Brown J et al.(2019). Faecal immunochemical tests versus colonoscopy for post-poly pectomy surveillance: An accuracy, acceptability and economic study. Health Technology Assessment vol. 23, (1) I-84.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH et al. (2018). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. JOURNAL OF CLINICAL ONCOLOGY. vol. 36,

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. (2017). A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. ANNALS OF ONCOLOGY. Conference: ESMO vol. 28,